KYMR:NASDAQKymera Therapeutics, Inc. Analysis
Data as of 2026-06-21 - not real-time
$90.43
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Kymera Therapeutics (KYMR) trades at $90.43, comfortably above its 20‑day, 50‑day and 200‑day moving averages, with a bullish MACD and an RSI near 67, indicating strong upward momentum despite a neutral overall trend. Volume is rising, supporting the price action, while the stock exhibits a high 30‑day volatility of roughly 47% but a modest beta under 1, suggesting price swings are company‑specific rather than market‑driven.
Fundamentally, the company posts impressive 55% revenue growth and a robust cash position of $650 M against $80 M of debt, yet it remains unprofitable with negative margins and a price‑to‑sales ratio exceeding 140, making valuation metrics like PE and P/B less informative. Analyst sentiment is very positive, with a strong‑buy consensus, a median price target of $119 and an implied upside of over 30%.
Fundamentally, the company posts impressive 55% revenue growth and a robust cash position of $650 M against $80 M of debt, yet it remains unprofitable with negative margins and a price‑to‑sales ratio exceeding 140, making valuation metrics like PE and P/B less informative. Analyst sentiment is very positive, with a strong‑buy consensus, a median price target of $119 and an implied upside of over 30%.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish technical setup (price above SMAs, MACD bullish)
- Elevated short‑term volatility
- Strong cash runway but ongoing losses
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Rapid revenue growth and expanding pipeline
- Analyst consensus strong‑buy with significant upside
- Increasing trading volume supporting price appreciation
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Potential value inflection from Phase 2/3 trial readouts
- Strategic partnership with Sanofi enhancing commercialization prospects
- Large cash reserve providing runway for continued R&D
Key Metrics & Analysis
Financial Health
Revenue Growth55.50%
P/E Ratio-20.8
ROE-27.09%
ROA-17.16%
Debt/Equity5.23
P/B Ratio4.8
Op. Cash Flow$-242580992
Free Cash Flow$-139262368
Industry P/E24.1
Technical Analysis
TrendNeutral
RSI67.0
Support$69.48
Resistance$92.47
MA 20$80.41
MA 50$83.06
MA 200$73.55
MACDBullish
VolumeIncreasing
Fear & Greed Index91.46
Valuation
Target Price$119.19
Upside/Downside31.80%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.92
Volatility47.47%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.